Sanofi (SNY) and Its Rivals Head to Head Contrast
Sanofi (NYSE: SNY) is one of 115 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Sanofi to similar companies based on the strength of its dividends, valuation, earnings, profitability, institutional ownership, analyst recommendations and risk.
Insider and Institutional Ownership
9.3% of Sanofi shares are held by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceuticals” companies are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 11.9% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of recent recommendations for Sanofi and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sanofi currently has a consensus price target of $53.50, indicating a potential upside of 8.02%. As a group, “Pharmaceuticals” companies have a potential upside of 22.84%. Given Sanofi’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Sanofi has less favorable growth aspects than its rivals.
Valuation and Earnings
This table compares Sanofi and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Sanofi||$43.62 billion||$13.09 billion||12.64|
|Sanofi Competitors||$8.08 billion||$2.64 billion||-0.36|
Sanofi has higher revenue and earnings than its rivals. Sanofi is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This table compares Sanofi and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Sanofi pays an annual dividend of $1.10 per share and has a dividend yield of 2.2%. Sanofi pays out 28.1% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 2.4% and pay out 70.7% of their earnings in the form of a dividend.
Risk & Volatility
Sanofi has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Sanofi’s rivals have a beta of 0.90, suggesting that their average stock price is 10% less volatile than the S&P 500.
Sanofi rivals beat Sanofi on 8 of the 15 factors compared.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company’s vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company’s vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.
Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.